Absci Corporation (ABSI) 12-Month Stock Forecast & Price Target Cone

$11.13 -8.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.95

Absci Corporation (ABSI) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.91B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ABSI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.13 (-8.02% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #383 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ABSI compare to OABI and NRC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ABSI?
▼

Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $10.95 (-1.63%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (6)Whales (17)SEC (10)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$13 Bull$10 Base$8 Bear
📬 FREE ABSI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABSI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY ABSI SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (39% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$9.10-0.3% Next Q
Q2 (-2Q)
39
Grade E$9.07+16.5% Next Q
Q3 (-1Q)
41
Grade D$10.57+5.3% Next Q
Current
44
Grade D$11.13-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ABSI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ABSI currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.60) and Max Pain ($11.69) forces dealer call-delta covering toward $13.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABSI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABSI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ABSI Position Size: $10,000

Shares at $11.13: 898.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $8.14
$7,314
$-2,686 (-26.9%)
12M Consensus BaseTarget $10.43
$9,371
$-629 (-6.3%)
12M Bull Case BreakoutTarget $13.18
$11,842
+$1,842 (+18.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$1174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1269%B
JP MorganUS Large-Cap ResearchSELL$958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABSI)

  • ✓Walkthrough of ABSI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABSI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +98.04%▲ ASCENDING CHANNEL
2026-11-03O $12.10H $12.10L $11.13C $11.13VOL 4.57M
RES: $13.05SUP: $8.43SMA50: $9.60SMA200: $6.58
$13.20$10.49$7.78$5.07$2.36RES $13.05SUP $8.43$11.132026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ABSI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ABSI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ABSI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABSI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABSI)

Health Care Rank #383 of 1016 ⚔️ OABI vs ABSI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ABSI vs. OABI, NRC, ICLR, CRL)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Absci Corporation (ABSI) ranks #383 by composite RQD confidence (44/100, grade D) and #265 by equity capitalization ($1.91B). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with ABSI at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ABSI ACTIVE
Absci Corporation
D 44/100 — — -35.0% -8.02% $1.91B Benchmark Subject
OABI
OmniAb Inc.
D 44/100 — — -22.6% -2.29% $742.9M /oabi-vs-absi →
NRC
NRC Health
C+ 67/100 44.8x — 21.0% +1.45% $527.1M /nrc-vs-absi →
ICLR
ICON plc
B 72/100 71.9x — 3.1% -1.91% $16.18B /iclr-vs-absi →
CRL
Charles River Laboratories International Inc.
C 64/100 — — 0.4% -4.44% $17.16B /crl-vs-absi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001672688

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Absci Corporation (ABSI) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $4.5M , and -100.0% cumulative change since FY2023) , GAAP net income of -$115.2M, operating cash flow of -$92.9M, and free cash flow of -$94.0M (-29.2% YoY). On the balance sheet, ABSI closed FY2025 with $216.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$115.2M -$92.9M -$94.0M $216.3M —
FY2024 (FY) 2024-12-31 $4.5M -$103.1M -$72.4M -$72.8M $213.6M —
FY2023 (FY) 2023-12-31 $5.7M -$110.6M -$64.6M -$64.6M — —

3. ABSI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ABSI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Absci Corporation (NASDAQ: ABSI) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.13 (-8.02% 1D, market cap $1.91B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABSI ranks #383 in composite RQD confidence.

How does ABSI compare to OABI and NRC in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ABSI carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OABI (OmniAb Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M) and NRC (NRC Health) posts a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ABSI?

Per ABSI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001672688), Absci Corporation generated $0 in revenue (-100.0% YoY), -$115.2M in net income, and -$94.0M in free cash flow against $216.3M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ABSI trading relative to its 50-day, 200-day, and 52-week technical levels?

ABSI last traded at $11.13 (-8.02% on volume of 4,566,029 shares), positioning the stock +15.94% above its 50-day simple moving average ($9.60) and +69.15% above its 200-day simple moving average ($6.58). Across its 52-week range of $2.24 to $12.55, ABSI sits at the 86.2% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.74 to $12.52).

ABSI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ABSI's 12-month stock price target?

Absci Corporation (ABSI) carries a 12-month consensus base price target of $10.43 (-6.3% from $11.13), with a bull-case target of $13.18 and a bear-case floor of $8.14.

Is ABSI stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ABSI D (Sell — SELL) with an RQD Confidence score of 44/100.

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ABSI — Absci Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:47Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 45 / D, labeled "Roarable Sell — Underperform / Distribution Warning," per the Roarable RQD rating.

  • Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -4.53%. For a prospective investor, the weakness here means the business is not currently generating cash returns on invested capital, so valuation support must come from elsewhere.
  • Whale 13F Flow (17 / 20): Per the Roarable RQD rating, this is the strongest pillar, reflecting institutional accumulation and options positioning. This is a meaningful upside driver in the rating, though it describes positioning rather than business earnings power.
  • Insider Conviction (3 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow and scores very low. A prospective investor should note the weak insider-conviction signal as a caution.
  • Macro Regime Fit (9 / 20): Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity read. This implies the stock moves roughly in line with the market, with limited defensive character from this pillar.
  • Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings are mixed-to-weak and present a valuation tradeoff: the reported figures do not show strong financial health.

Overall, the rating's sell label rests mainly on negative cash generation and a weak forensic profile, partly offset by institutional positioning. This is an analytical framing, not personalized advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-120.3M$-115.2MN/A$-94.0M$20.0MN/A
FY 2024$4.5M$-108.9M$-103.1MN/A$-72.8M$41.2MN/A
FY 2023$5.7M$-115.5M$-110.6MN/A$-64.6MN/AN/A

Per the SEC financials, revenue declined from $5.7M (FY 2023) to $4.5M (FY 2024) to $0.0M (FY 2025), while operating losses remained large in each period. Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Per the Roarable RQD rating, Debt/Equity is 0.5; the debt figure in the SEC financials is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items relate to ABSI, sourced from Yahoo! Finance Canada, Yahoo Finance, TradingView, MarketBeat (two items), and a siam.in-sourced item. Headlines include a stock-price and news-quote page, a book-value valuation piece tagged as a catalyst, an estimates page, two MarketBeat items reporting a 13.2% jump and a 5.5% decline, and a report of a 13.47% slide to $10.47 toward key support. Per the feed, these items carry mixed light signals (YELLOW and GREEN). Risk watch items include the reported slide and the book-value framing. The Butterfly Supply-Chain Graph reports no proprietary signals.

Open Questions

  • What is the company's product and revenue model, given that FY 2025 revenue is reported as $0.0M?
  • What is the FY 2025 debt figure and the FY 2023 cash balance, both reported as N/A?
  • What are the TTM EPS and P/E ratios, which the source data does not provide?
  • Who are the institutional and insider holders behind the whale 13F and insider pillar scores?
  • What drove the reported 13.47% slide and the 13.2% jump in the news feed?

ABSI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Absci Corporation (ABSI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ABSI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ABSI Bull vs. Bear Conversation Board — What's Your Call at $11.13?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ABSI 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ABSI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $10.65 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ABSI (D • RQD 45/100) a Buy at $12.10?

Welcome to the ABSI (Absci Corporation) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.68 (-20.0%)
Spot @ $12.10

Pump the brakes on ABSI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ABSI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Absci Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $15.49 (+28.0%)
Spot @ $12.10

ABSI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ABSI, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $12.10 (52-wk range $2.24 - $12.55), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%